SCHEMBL3602067

SCHEMBL3602067

COc1ccc(-c2nc(C=O)cs2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.67
ALDH1A1 P00352 7/20 0.64
KDM4E B2RXH2 6/20 0.58
GAA P10253 2/20 0.58
HPGD P15428 1/20 0.58
TDP1 Q9NUW8 1/20 0.57
MEN1 O00255 2/20 0.52
RAB9A P51151 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 1/20 0.52
TLR7 Q9NYK1 1/20 0.49
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48
HTR7 P34969 2/20 0.46
LMNA P02545 1/20 0.45
ERN1 O75460 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003043 0.84 MAPT (0.58) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL2764359 0.84 MAPT (0.60) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL3591035 0.82 MAPT (0.55) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL6198667 0.78 ALDH1A1 (0.72) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL27995818 0.78 ALDH1A1 (0.84) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL5532236 0.77 ALDH1A1 (0.74) MAPTALDH1A1KDM4EHPGDTDP1
SCHEMBL13815761 0.76 HTR2B (0.60) MAPTALDH1A1KDM4EHPGDTDP1
SCHEMBL9782130 0.75 ALDH1A1 (1.00) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL28731315 0.75 MAPT (0.65) MAPTALDH1A1ERN1
SCHEMBL4539676 0.74 MAPT (0.69) MAPTALDH1A1KDM4EGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104610230-A Compounds for the treatment of cancer UNIV TENNESSEE RES FOUNDATION 2015-05-13 CN disclosed
CN-102137592-B Compounds for the treatment of cancer UNIV TENNESSEE RES FOUNDATION (US) 2015-01-28 CN disclosed
US-8450352-B2 Thiazole compounds and their use for inhibiting phosphodiesterase 4, TNF-α, and IL-4 OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-05-28 US disclosed
US-20100094002-A1 Thiazole Compound and Use Thereof OTSUKA PHARMACEUTICAL CO., LTD. 2010-04-15 US disclosed
US-7655680-B2 (E)-3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-1-(2-methoxyphenyl)propenone; inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4; atopic dermatitis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-02-02 US disclosed
US-20080039511-A1 Thiazole Compound and Use Thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-02-14 US disclosed
EP-1748044-A1 THIAZOLE COMPOUND AND USE THEREOF Otsuka Pharmaceutical Company, Limited (JP) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094002-A1 Thiazole Compound and Use Thereof PDE3B, IL4, PDE4A MAPT 4535/4885ALDH1A1 534/4885KDM4E 2320/4885
US-20080039511-A1 Thiazole Compound and Use Thereof PDE3B, PDE3A, PDE4A MAPT 4658/4885ALDH1A1 453/4885KDM4E 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.